Johannes-Peter Stasch

Johannes-Peter Stasch

UNVERIFIED PROFILE

Are you Johannes-Peter Stasch?   Register this Author

Register author
Johannes-Peter Stasch

Johannes-Peter Stasch

Publications by authors named "Johannes-Peter Stasch"

Are you Johannes-Peter Stasch?   Register this Author

100Publications

2089Reads

34Profile Views

Correction to: Soluble Guanylate Cyclase Stimulators and Activators.

Handb Exp Pharmacol 2019 Jul 5. Epub 2019 Jul 5.

Bayer AG, Pharmaceuticals R&D, Pharma Research Center, Wuppertal, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/164_2019_249DOI Listing
July 2019

Soluble Guanylate Cyclase Stimulators and Activators.

Handb Exp Pharmacol 2019 Jan 29. Epub 2019 Jan 29.

Bayer AG, Pharmaceuticals R&D, Pharma Research Center, Wuppertal, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/164_2018_197DOI Listing
January 2019

Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases.

Nitric Oxide 2018 07 5;77:88-95. Epub 2018 May 5.

Bayer AG, Pharmaceuticals Division, Research & Development - Cardiovascular Research, Wuppertal, Wuppertal, Germany; University Halle-Wittenberg, Institute of Pharmacy, Halle, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.niox.2018.05.001DOI Listing
July 2018

Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease.

Redox Biol 2018 04 8;14:328-337. Epub 2017 Sep 8.

Cardiovascular Research Laboratory, Division of Cardiology, Pneumology and Vascular Medicine, Medical Faculty, Heinrich Heine University, Moorenstraße 5, 40225 Düsseldorf, Germany; CARID, Cardiovascular Research Institute Düsseldorf, Medical Faculty, Heinrich Heine University, Moorensstraße 5, 40225 Düsseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.redox.2017.08.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975213PMC
April 2018

Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.

Chest 2017 02 2;151(2):468-480. Epub 2016 Jun 2.

Division of Pulmonary, Sleep, and Critical Care Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chest.2016.05.024DOI Listing
February 2017

Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence.

Respir Med 2017 01 25;122 Suppl 1:S1-S9. Epub 2016 Aug 25.

Bayer HealthCare AG, Drug Discovery, Wuppertal, Germany; Institute of Pharmacy, University of Halle-Wittenberg, Halle (Saale), Germany.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09546111163021
Publisher Site
http://dx.doi.org/10.1016/j.rmed.2016.08.022DOI Listing
January 2017

Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.

Int J Cardiol 2016 Aug 16;216:85-91. Epub 2016 Apr 16.

Excellence Cluster Cardio-Pulmonary System, Universities of Giessen and Marburg Lung Center, Member of the German Lung Center, Justus Liebig University Giessen, Giessen, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2016.04.098DOI Listing
August 2016

Translational In Vivo Models for Cardiovascular Diseases.

Handb Exp Pharmacol 2016 ;232:223-34

Bayer HealthCare AG, Cardiovascular I/III, Aprather Weg 18a, 42096, Wuppertal, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/164_2015_31DOI Listing
June 2016

The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.

Eur J Pharmacol 2015 Nov 25;767:1-9. Epub 2015 Sep 25.

Department of Internal Medicine B, Cardiology, University Medicine Greifswald, Germany; DZHK (German Centre for Cardiovascular Research), partner site Greifswald, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2015.09.022DOI Listing
November 2015

Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence.

Curr Opin Pharmacol 2015 Apr 31;21:95-104. Epub 2015 Jan 31.

University of Potsdam, Potsdam, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coph.2014.12.014DOI Listing
April 2015

α1-A680T variant in GUCY1A3 as a candidate conferring protection from pulmonary hypertension among Kyrgyz highlanders.

Circ Cardiovasc Genet 2014 Dec 4;7(6):920-9. Epub 2014 Nov 4.

From the Department of Medicine, Imperial College London, London, United Kingdom (M.R.W., J.W., C.J.R., S.R.); National Academy of Sciences of Kyrgyz Republic, Bishkek, Kyrgyz Republic (A.A.A.); Physiological Genomics and Medicine Group, MRC Clinical Sciences Centre, Hammersmith Hospital, London, United Kingdom (J.V., T.J.A.); NIHR BRC Clinical Genome Informatics Facility, Imperial College London, London, United Kingdom (D.K., S.G.B., M.M.); Cardiology Research, Bayer Pharma AG, Wuppertal, Germany (S.G., J.-P.S.); Department of Pharmacology, The School of Pharmacy, Martin-Luther-University, Halle, Germany (J.-P.S.); Department of Pulmonary Pharmacotherapy, University of Giessen and Marburg Lung Center, Giessen, Germany (B.K.); Department of Medicine, University of Cambridge, Cambridge, United Kingdom (N.W.M.); Department of Pharmacology, Toxicology, and Clinical Pharmacy, University of Braunschweig-Center of Pharmaceutical Engineering, Braunschweig, Germany (I.N., S.B.); and Department of Chemistry, The Scripps Research Institute, La Jolla, CA (N.B.S., M.A.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCGENETICS.114.000763DOI Listing
December 2014

Influence of cinaciguat on gastrointestinal motility in apo-sGC mice.

Neurogastroenterol Motil 2014 Nov 8;26(11):1573-85. Epub 2014 Sep 8.

Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/nmo.12424DOI Listing
November 2014

Role of soluble guanylate cyclase in renal hemodynamics and autoregulation in the rat.

Am J Physiol Renal Physiol 2014 Nov 10;307(9):F1003-12. Epub 2014 Sep 10.

Physiologisches Institut, Albert-Ludwigs-Universität, Freiburg, Germany; and

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajprenal.00229.2014DOI Listing
November 2014

Soluble guanylate cyclase stimulators in pulmonary hypertension.

Handb Exp Pharmacol 2013 ;218:279-313

Cardiology Research, Bayer Pharma AG, Aprather Weg 18a, 42096, Wuppertal, Germany,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-642-38664-0_12DOI Listing
July 2014

Structure/activity relationships of (M)ANT- and TNP-nucleotides for inhibition of rat soluble guanylyl cyclase α1β1.

Mol Pharmacol 2014 Apr 27;85(4):598-607. Epub 2014 Jan 27.

Department of Medicinal Chemistry II, University of Regensburg, Regensburg, Germany (S.D.); Institute of Pharmacology,(K.Y.D., V.K., R.S.) and Research Core Unit Metabolomics (V.K.), Hannover Medical School, Hannover, Germany; and Institute of Cardiovascular Research, Bayer HealthCare, Wuppertal, Germany (J.-P.S.).

View Article

Download full-text PDF

Source
http://molpharm.aspetjournals.org/cgi/doi/10.1124/mol.113.09
Publisher Site
http://dx.doi.org/10.1124/mol.113.091017DOI Listing
April 2014

Attenuated response of L-type calcium current to nitric oxide in atrial fibrillation.

Cardiovasc Res 2014 Mar 12;101(3):533-42. Epub 2013 Dec 12.

Department of Pharmacology and Toxicology, Dresden University of Technology, Dresden, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/cvr/cvt334DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014863PMC
March 2014

NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size.

Cardiovasc Res 2014 Feb 20;101(2):220-8. Epub 2013 Nov 20.

School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/cvr/cvt257DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896250PMC
February 2014

Nucleotidyl cyclase activity of soluble guanylyl cyclase in intact cells.

Biochem Biophys Res Commun 2014 Jan 28;443(4):1195-9. Epub 2013 Dec 28.

Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2013.12.108DOI Listing
January 2014

Receptor binding assay for NO-independent activators of soluble guanylate cyclase.

Methods Mol Biol 2013 ;1020:205-14

CSL Limited, BIO21 Institute, Parkville, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-62703-459-3_13DOI Listing
December 2013

The chemistry and biology of soluble guanylate cyclase stimulators and activators.

Angew Chem Int Ed Engl 2013 Sep 20;52(36):9442-62. Epub 2013 Aug 20.

Bayer Pharma Aktiengesellschaft, Global Drug Discovery, Aprather Weg 18a, 42113 Wuppertal, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/anie.201302588DOI Listing
September 2013

Analysis of erectile responses to BAY 41-8543 and muscarinic receptor stimulation in the rat.

J Sex Med 2013 Mar 18;10(3):704-18. Epub 2012 Sep 18.

Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA 70112-2699, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1743-6109.2012.02912.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594361PMC
March 2013

Identification of acidic heterocycle-substituted 1H-pyrazolo[3,4-b]pyridines as soluble guanylate cyclase stimulators.

Bioorg Med Chem Lett 2013 Mar 16;23(5):1197-200. Epub 2013 Jan 16.

Bayer Pharma AG, Global Drug Discovery, Medicinal Chemistry Wuppertal, D-42096 Wuppertal, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2013.01.028DOI Listing
March 2013

The selective Rho-kinase inhibitor azaindole-1 has long-lasting erectile activity in the rat.

Urology 2013 Feb;81(2):465.e7-14

Department of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana 70112-2699, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2012.10.039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564057PMC
February 2013

Early urinary and plasma biomarkers for experimental diabetic nephropathy.

Clin Lab 2012 ;58(7-8):659-71

Center for Cardiovascular Research/Institute of Pharmacology, Charité, Campus Mitte, Berlin, Germany.

View Article

Download full-text PDF

Source
October 2012

Tetrahydrobiopterin protects soluble guanylate cyclase against oxidative inactivation.

Mol Pharmacol 2012 Sep 30;82(3):420-7. Epub 2012 May 30.

Department of Pharmacology and Toxicology, Karl-Franzens-Universität Graz, Graz, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/mol.112.079855DOI Listing
September 2012

The Rho kinase inhibitor azaindole-1 has long-acting vasodilator activity in the pulmonary vascular bed of the intact chest rat.

Can J Physiol Pharmacol 2012 Jul 16;90(7):825-35. Epub 2012 May 16.

Department of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana 70112-2699, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1139/y2012-061DOI Listing
July 2012

Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide.

Am J Physiol Heart Circ Physiol 2012 Mar 20;302(6):H1347-54. Epub 2012 Jan 20.

Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University Medical Center, Richmond, USA.

View Article

Download full-text PDF

Source
http://ajpheart.physiology.org/content/ajpheart/302/6/H1347.
Web Search
http://ajpheart.physiology.org/cgi/doi/10.1152/ajpheart.0054
Publisher Site
http://dx.doi.org/10.1152/ajpheart.00544.2011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3311478PMC
March 2012

Nucleotidyl cyclase activity of soluble guanylyl cyclase α1β1.

Biochemistry 2012 Jan 13;51(1):194-204. Epub 2011 Dec 13.

Institute of Pharmacology, Hannover Medical School, Hannover, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi201259yDOI Listing
January 2012

Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension.

Am J Physiol Lung Cell Mol Physiol 2011 Nov 19;301(5):L755-64. Epub 2011 Aug 19.

Pediatric Heart Lung Center, Sections of Neonatology and Pulmonary Medicine, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajplung.00138.2010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3213988PMC
November 2011

Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.

Circulation 2011 May;123(20):2263-73

Institute of Pharmacy, Martin Luther University, Halle, and the Cardiology Research, Bayer HealthCare AG, Wuppertal, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.110.981738DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3103045PMC
May 2011

Riociguat for the treatment of pulmonary hypertension.

Expert Opin Investig Drugs 2011 Apr 11;20(4):567-76. Epub 2011 Mar 11.

Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1517/13543784.2011.5
Publisher Site
http://dx.doi.org/10.1517/13543784.2011.565048DOI Listing
April 2011

Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass.

Eur J Cardiothorac Surg 2011 Feb 29;39(2):248-55. Epub 2010 Jun 29.

Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejcts.2010.05.025DOI Listing
February 2011

BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats.

Eur J Pharmacol 2010 Nov 7;647(1-3):147-54. Epub 2010 Sep 7.

Department of Pharmacology, Faculty of Health Sciences, Aarhus University, Aarhus C, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2010.08.032DOI Listing
November 2010

Kynurenine is an endothelium-derived relaxing factor produced during inflammation.

Nat Med 2010 Mar 28;16(3):279-85. Epub 2010 Feb 28.

Centre for Vascular Research, School of Medical Sciences (Pathology) and Bosch Institute, Faculty of Medicine, University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.2092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3556275PMC
March 2010

Soluble guanylate cyclase agonists inhibit expression and procoagulant activity of tissue factor.

Arterioscler Thromb Vasc Biol 2009 Oct 10;29(10):1578-86. Epub 2009 Jul 10.

Department of Medicine, University Hospital of Northern Norway, Tromsø, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/ATVBAHA.109.192690DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938177PMC
October 2009

Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart.

Hypertens Res 2009 Jul 8;32(7):597-603. Epub 2009 May 8.

Department of Internal Medicine, Circulatory and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/hr.2009.64DOI Listing
July 2009

Novel soluble guanylyl cyclase stimulator BAY 41-2272 attenuates ischemia-reperfusion-induced lung injury.

Am J Physiol Lung Cell Mol Physiol 2009 Mar 12;296(3):L462-9. Epub 2008 Dec 12.

Departments of Internal Medicine II, University Hospital Giessen and Marburg, Giessen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajplung.90377.2008DOI Listing
March 2009

NO-independent, haem-dependent soluble guanylate cyclase stimulators.

Handb Exp Pharmacol 2009 (191):277-308

Bayer Schering Pharma AG, Cardiology Research, Pharma Research Center, Wuppertal, 42096, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-540-68964-5_13DOI Listing
March 2009

NO- and haem-independent soluble guanylate cyclase activators.

Handb Exp Pharmacol 2009 (191):309-39

Department of Pharmacology and Centre for Vascular Health, Monash University, Clayton, VIC, 3800, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-540-68964-5_14DOI Listing
March 2009

Gender-dependent impact of risk factors for cardiovascular and non-cardiovascular mortality in end-stage renal disease patients on haemodialysis.

Kidney Blood Press Res 2008 20;31(5):360-6. Epub 2008 Nov 20.

Center for Cardiovascular Research/Department of Pharmacology, Charité, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000173718DOI Listing
February 2009

Additional lack of iNOS attenuates diastolic dysfunction in aged ET-1 transgenic mice.

Can J Physiol Pharmacol 2008 Jun;86(6):353-7

Center for Cardiovascular Research, Department of Pharmacology and Toxicology, Charite, Hessische Str. 3-4, Berlin 10115, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1139/Y08-032DOI Listing
June 2008

Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation.

Am J Respir Crit Care Med 2007 Dec 13;176(11):1138-45. Epub 2007 Sep 13.

Department of Anesthesia and Critical Care, Massachusetts General Hospital, 55 Fruit Street, Gray/Bigelow 444, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1164/rccm.200707-1121OCDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2176100PMC
December 2007

Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure.

Hypertension 2007 May 26;49(5):1128-33. Epub 2007 Feb 26.

Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.106.
Publisher Site
http://dx.doi.org/10.1161/HYPERTENSIONAHA.106.083832DOI Listing
May 2007

Soluble CD154 is a unique predictor of nonfatal and fatal atherothrombotic events in patients who have end-stage renal disease and are on hemodialysis.

J Am Soc Nephrol 2007 Apr 21;18(4):1323-30. Epub 2007 Feb 21.

Center for Cardiovascular Research/Institute of Pharmacology, Charité-Universitätsmedizin Berlin, Hessische Strasse 3-4, 10115 Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1681/ASN.2006070684DOI Listing
April 2007

Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats.

Hypertension 2006 Nov 18;48(5):972-8. Epub 2006 Sep 18.

Department of Internal Medicine, Circulatory and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki, 5200 Kihara Kiyotake, Miyazaki 889-1692, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/01.HYP.0000241087.12492.47DOI Listing
November 2006

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Nat Rev Drug Discov 2006 Sep;5(9):755-68

Department of Anesthesia and Critical Care, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, CLN 309, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd2038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2225477PMC
September 2006

NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy.

Br J Pharmacol 2006 Jul 12;148(6):853-9. Epub 2006 Jun 12.

Department of Pharmacology and Toxicology, Center for Cardiovascular Research, Charité, Campus Mitte, Hessische Str. 3-4, Berlin D-10115, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.bjp.0706792DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1617071PMC
July 2006

Identification of residues crucially involved in soluble guanylate cyclase activation.

FEBS Lett 2006 Jul 5;580(17):4205-13. Epub 2006 Jul 5.

Cardiovascular Research, Bayer HealthCare, Aprather Weg 18a, D-42096 Wuppertal, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.febslet.2006.06.079DOI Listing
July 2006

Humoral and hemodynamic responses after left ventricular assist device implantation and heart transplantation.

Exp Biol Med (Maywood) 2006 Jun;231(6):861-4

Deutsches Herzzentrum Berlin, Germany.

View Article

Download full-text PDF

Source
June 2006

Diabetic endothelin B receptor-deficient rats develop severe hypertension and progressive renal failure.

J Am Soc Nephrol 2006 Apr 22;17(4):1082-9. Epub 2006 Feb 22.

Center for Cardiovascular Research/Institute of Pharmacology, Charité Mitte, Hessische Strasse 3-4, 10115 Berlin, Germany.

View Article

Download full-text PDF

Source
http://www.jasn.org/cgi/doi/10.1681/ASN.2005080833
Publisher Site
http://dx.doi.org/10.1681/ASN.2005080833DOI Listing
April 2006

Selective indole-based ECE inhibitors: synthesis and pharmacological evaluation.

ChemMedChem 2006 Jan;1(1):96-105

Bayer HealthCare AG, Business Group Pharma, Research & Development, Aprather Weg 18a, 42096 Wuppertal, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cmdc.200500009DOI Listing
January 2006

Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis.

Am J Physiol Renal Physiol 2005 Apr 23;288(4):F685-93. Epub 2004 Nov 23.

Div. of Nephrology, Univ. Erlangen-Nuremberg, Loschgestrasse 8, 91054 Erlangen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajprenal.00280.2004DOI Listing
April 2005

A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway.

Anal Biochem 2005 Apr;339(1):104-12

Institute of Cardiovascular Research, Bayer HealthCare AG, D-42096 Wuppertal, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ab.2004.12.025DOI Listing
April 2005

Residues stabilizing the heme moiety of the nitric oxide sensor soluble guanylate cyclase.

Eur J Pharmacol 2005 Apr 8;513(1-2):67-74. Epub 2005 Apr 8.

Institute of Cardiovascular Research, Bayer Healthcare, Wuppertal, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2005.02.046DOI Listing
April 2005

New antithrombotics with an indazole structure.

Arch Pharm (Weinheim) 2004 Jun;337(6):311-6

Institut für Pharmazie, Freie Universität Berlin, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ardp.200300832DOI Listing
June 2004